Suppr超能文献

核受体中的变构途径——药物设计的潜在靶点。

Allosteric pathways in nuclear receptors - Potential targets for drug design.

机构信息

Department of Biochemistry & Cellular and Molecular Biology, The University of Tennessee, USA.

出版信息

Pharmacol Ther. 2018 Mar;183:152-159. doi: 10.1016/j.pharmthera.2017.10.014. Epub 2017 Oct 31.

Abstract

The nuclear receptor family of transcription factor proteins mediates endocrine function and plays critical roles in the development, physiology and pharmacology. Malfunctioning nuclear receptors are associated with several disease states. The functional activity of nuclear receptors is regulated by small molecular hormonal and synthetic molecules. Multiple sources of evidence have identified and distinguished between the different allosteric pathways initiated by ligands, DNA and cofactors such as co-activators and co-repressors. Also, these biophysical studies are attempting to determine how these pathways that regulate co-activator and DNA recognition can control gene transcription. Thus, there is a growing interest in determining the genome-scale impact of allostery in nuclear receptors. Today, it is accepted that a detailed understanding of the allosteric regulatory pathways within the nuclear receptor molecular complex will enable the development of efficient drug therapies in the long term.

摘要

核受体转录因子家族介导内分泌功能,在发育、生理学和药理学中发挥关键作用。功能失常的核受体与多种疾病状态有关。核受体的功能活性受小分子激素和合成分子的调节。多种来源的证据已经确定并区分了配体、DNA 和辅助因子(如共激活因子和共抑制因子)启动的不同变构途径。此外,这些生物物理研究还试图确定这些调节共激活因子和 DNA 识别的途径如何控制基因转录。因此,人们越来越感兴趣的是确定核受体变构作用对基因组的影响。如今,人们普遍认为,详细了解核受体分子复合物中的变构调节途径将能够从长远来看开发出有效的药物治疗方法。

相似文献

1
Allosteric pathways in nuclear receptors - Potential targets for drug design.核受体中的变构途径——药物设计的潜在靶点。
Pharmacol Ther. 2018 Mar;183:152-159. doi: 10.1016/j.pharmthera.2017.10.014. Epub 2017 Oct 31.
2
Allosteric controls of nuclear receptor function in the regulation of transcription.核受体转录调控的变构控制。
J Mol Biol. 2013 Jul 10;425(13):2317-29. doi: 10.1016/j.jmb.2013.03.017. Epub 2013 Mar 15.
3
Allosteric small molecule modulators of nuclear receptors.核受体的变构小分子调节剂。
Mol Cell Endocrinol. 2019 Apr 5;485:20-34. doi: 10.1016/j.mce.2019.01.022. Epub 2019 Jan 28.
7
Nuclear receptor coactivators.核受体共激活因子
Curr Opin Cell Biol. 1997 Apr;9(2):222-32. doi: 10.1016/s0955-0674(97)80066-x.
8
The association between nuclear receptors and ocular diseases.核受体与眼部疾病之间的关联。
Oncotarget. 2017 Apr 18;8(16):27603-27615. doi: 10.18632/oncotarget.15178.
10
Non-canonical modulators of nuclear receptors.核受体的非经典调节剂。
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4157-64. doi: 10.1016/j.bmcl.2016.07.067. Epub 2016 Jul 29.

引用本文的文献

10
Advances in targeting 'undruggable' transcription factors with small molecules.小分子靶向“不可成药”转录因子的研究进展。
Nat Rev Drug Discov. 2021 Sep;20(9):669-688. doi: 10.1038/s41573-021-00199-0. Epub 2021 May 18.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验